NCT05844033Active, not recruiting
Biomarker for Infection Risk in CLL and MM
Biomarker for Infection Risk in Chronic Lymphocytic Leukemia and Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 19 May 2026
Brief summary (registry, in English)
The aim of this research study is to use advanced immunology laboratory analysis to identify a more precise blood test that will predict infection risk in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) or Multiple Myeloma (MM).
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 13 Apr 2023
- Start date
- 1 Aug 2023
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Massachusetts General Hospital
- NCT number
- NCT05844033
What you commit to
- Study type: Observational
- Planned participants: 150
- From 1 Aug 2023 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects must not have received IVIG administration within 6 calendar months of registration or have planned immunoglobulin replacement therapy by treating investigator at time of registration.
- Subjects must not have undergone prior autologous, allogeneic stem cell, or solid organ transplant.
- Subjects must have no known history of HIV, primary immune deficiency disorder, nor be taking a concurrent immune suppressing medication at time of registration. Treatment for CLL/SLL or MM, CLL/SLL related autoimmune phenomenon, or physiologic dosing of corticosteroids (5mg/day prednisone/equivalent or lower) is permitted.
Other illness
- Subjects must not have any active systemic infection requiring ongoing antimicrobial treatment (prophylactic antimicrobial allowed) at time of registration.
Other
- Subjects with chronic lymphocytic leukemia or small lymphocytic lymphoma must not be Rai stage 0.
- Subjects with multiple myeloma must not have smoldering myeloma or solitary plasmacytoma with or without minimal marrow involvement.
Who the study is looking for
- Adults ≥18 years of age.
- Diagnosis of Rai stage I-IV chronic lymphocytic leukemia or small lymphocytic lymphoma or multiple myeloma.
- Subjects must be able to consent to clinical trial, or documented health care proxy agent able to consent on behalf of participant.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts General Hospital Cancer Center Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.